TIDMYGEN
RNS Number : 1285J
Yourgene Health PLC
25 April 2022
Yourgene Health plc
("Yourgene" or the "Company")
Strategic partnership extended with Ambry Genetics
Expanding market access of technology
Manchester, UK - 25 April 2022: Yourgene (AIM: YGEN), a leading
international molecular diagnostics group, announces the Company
has extended its strategic partnership with Ambry Genetics
('Ambry'), a leading US precision medicine company, with a new
Genomic Services collaboration. The new agreement will allow both
companies access to each other's technology and assays, expanding
market access and penetration for both.
On 9 June 2021 Yourgene announced a multi-year licence and
supply agreement with an unnamed US partner (the 'Partner') for
access to the Company's Noninvasive prenatal testing (NIPT)
technology which came into effect on 1 April 2022. Yourgene can now
confirm that the Partner is Ambry Genetics, a part of REALM IDx,
Inc.
The agreement will enable the development of NIPT-related
solutions as a part of Ambry's Women's Health portfolio expansion.
Along with carrier screening, the portfolio will include Ambry's
CARE (Comprehensive Assessment Risk and Education) Program, a
digital tool that provides a streamlined, end-to-end solution for
physicians to provide risk screening and education on genetic
testing, as well as facilitate test ordering, result reporting and
access to genetic counselors.
Currently, Ambry's CARE Program is being used to help identify
patients at higher risk of developing cancer, but it will be
expanded to include NIPT and Carrier Screening to provide
physicians one easy-to-use platform with a comprehensive set of
genetic testing, education and support options for their
patients.
"To truly add value for physicians, you need to have a robust
screening technology along with a delivery program that helps to
educate and ensure that patients understand the testing that they
are being offered" said Tom Schoenherr, Chief Executive Officer of
Ambry Genetics. "We believe the partnership with Yourgene and our
CARE Program will help to standardize informed care and remove
disparities in its delivery."
Yourgene expects that this partnership will underpin its future
growth and create a greater number of commercial opportunities for
both companies.
Lyn Rees, Chief Executive Officer, commented: "This is a
multi-level partnership with a leader in the field of precision
medicine. Ambry will provide an addressable US market for NIPT and
a range of class leading oncology products and services to bring to
our recently expanded UK based genomic services footprint. We very
much look forward to strengthening and broadening our relationship
with Ambry, cementing our relationship with this prestigious US
company."
This announcement contains inside information for the purposes
of the UK Market Abuse Regulation.
The Directors of the Company take responsibility for this
announcement.
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Cairn Financial Advisers LLP (NOMAD) Tel: +44 (0)20 7213 0880
Liam Murray / James Caithie / Ludovico
Lazzaretti
Singer Capital Markets (Joint Corporate Tel: +44 (0)20 7496 3000
Broker)
Aubrey Powell / Tom Salvesen / George
Tzimas
Stifel Nicolaus Europe Limited (Joint Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations)
Paul McManus / Lianne Applegarth Mob: 07980 541 893 / 07584 391 303
/ Alice Woodings / 07407 804 654
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops integrated genomic technologies and services
enabling genomic medicine. The group works in partnership with
global leaders in DNA technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises
simple and accurate molecular diagnostic solutions, for
reproductive health, precision medicine and now infectious
diseases. The Group's flagship products include non-invasive
prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests, and a recent extension into the oncology space
with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to
offer a global laboratory service network equipped to be a full
life-cycle partner for clinical, research and pharmaceutical
organisations to support partners at the preclinical, clinical, and
post-market stages to develop, manufacture, obtain regulatory
approval and commercialise new products and services. In addition,
Yourgene Genomic Services offers an NIPT and high throughput COVID
testing service.
In August 2020, Yourgene acquired Coastal Genomics , Inc., a
sample preparation technology company based in Vancouver, Canada,
enabling the Company to extend its offering and IP portfolio in the
DNA sample preparation sector. The acquisition increased Yourgene's
geographical penetration into the US and Canada, supplementing
existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei, Singapore, the US and Canada, and is listed on the
London Stock Exchange's AIM market under the ticker "YGEN". For
more information visit www.yourgene-health.com and follow us on
twitter @Yourgene_Health.
About Ambry Genetics
Ambry Genetics, a part of REALM IDx, Inc., translates scientific
research into clinically actionable test results based upon a deep
understanding of the human genome and the biology behind genetic
disease. It is a leader in genetic testing that aims to improve
health by understanding the relationship between genetics and
disease. Its unparalleled track record of discoveries over 20
years, and growing database that continues to expand in
collaboration with academic, corporate and pharmaceutical partners,
means Ambry Genetics is first to market with innovative products
and comprehensive analysis that enable clinicians to confidently
inform patient health decisions.
Media Contacts
Brad Lotterman
REALM IDx Communications Director
blotterman@realmidx.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEAKLLADXAEFA
(END) Dow Jones Newswires
April 25, 2022 02:00 ET (06:00 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024
